Pathway-based gene signatures predicting clinical outcome of lung adenocarcinoma

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Chang, Ya Hsuan ^a   Chen, Chung Ming ^a   Chen, Hsuan Yu ^b   Yang, Pan Chyr ^c  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b INSTITUTE OF STATISTICAL SCIENCE   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; BETA ADRENERGIC RECEPTOR; HIGH MOBILITY GROUP B1 PROTEIN; TRANSCRIPTOME;

ADENOCARCINOMA; CLATHRIN-COATED VESICLE; COHORT ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; KAPLAN MEIER METHOD; LUNG TUMOR; METABOLISM; MORTALITY; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REPRODUCIBILITY; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; CARCINOMA, NON-SMALL-CELL LUNG; CLATHRIN-COATED VESICLES; COHORT STUDIES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HMGB1 PROTEIN; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; PATIENT OUTCOME ASSESSMENT; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ADRENERGIC, BETA; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION; TRANSCRIPTOME;

EID: 84930676348     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep10979     Document Type: Article

References (38)

1. Siegel R., Naishadham D. & Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 62, 10-29 (2012
2. Herbst R. S., Heymach J. V. & Lippman S. M. Lung cancer. N. Engl. J. Med. 359, 1367-1380 (2008
3. Molina J. R., Yang P., Cassivi S. D., Schild S. E. & Adjei A. A. Non-small cell lung cancer:epidemiology, risk factors, treatment, and survivorship. Mayo Clin. Proc. 83, 584-594 (2008
4. Chen H. Y., Yu S. L., Li K. C. & Yang P. C. Biomarkers and transcriptome profiling of lung cancer. Respirology 17, 620-626 (2012
5. Singhal S., Miller D., Ramalingam S. & Sun S. Y. Gene expression profiling of non-small cell lung cancer. Lung Cancer 60, 313-324 (2008
6. Kadara H., et al. A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis. Clin. Cancer Res. 17, 1490-1501 (2011
7. Shedden K., et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat. Med. 14, 822-827 (2008
8. Lindeman N. I., et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J. Thorac. Oncol. 8, 823-859 (2013
9. Subramanian A., et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U. S. A. 102, 15545-15550 (2005
10. Hung J. H. Gene Set/Pathway enrichment analysis. Methods Mol. Biol. 939, 201-213 (2013
11. Allison D. B., Cui X., Page G. P. & Sabripour M. Microarray data analysis: from disarray to consolidation and consensus. Nat. Rev. Genet. 7, 55-65 (2006
12. Ackermann M. & Strimmer K. A general modular framework for gene set enrichment analysis. BMC Bioinformatics 10, 47 (2009
13. Nam D. & Kim S. Y. Gene-set approach for expression pattern analysis. Brief. Bioinformatics 9, 189-197 (2008
14. Wan Y. W., Beer D. G. & Guo N. L. Signaling pathway-based identification of extensive prognostic gene signatures for lung adenocarcinoma. Lung Cancer 76, 98-105 (2012
15. Sudhindra A., Ochoa R. & Santos E. S. Biomarkers, prediction, and prognosis in non-small-cell lung cancer: a platform for personalized treatment. Clin. Lung Cancer 12, 360-368 (2011
16. Lu T. P., Chuang E. Y. & Chen J. J. Identification of reproducible gene expression signatures in lung adenocarcinoma. BMC Bioinformatics 14, 371 (2013
17. DerSimonian R. & Laird N. Meta-analysis in clinical trials. Control. Clin. Trials 7, 177-188 (1986
18. Weiss G. J. & Kingsley C. Pathway targets to explore in the treatment of non-small cell lung cancer. J. Thorac. Oncol. 3, 1342-1352 (2008
19. Daraselia N., et al. Molecular signature and pathway analysis of human primary squamous and adenocarcinoma lung cancers. Am. J. Cancer Res. 2, 93-103 (2012
20. Thomassen M., et al. Comparison of gene sets for expression profiling: prediction of metastasis from low-malignant breast cancer. Clin. Cancer Res. 13, 5355-5360 (2007
21. Dong Y. D., et al. Expression and clinical significance of HMGB1 in human liver cancer: Knockdown inhibits tumor growth and metastasis in vitro and in vivo. Oncol. Rep. 29, 87-94 (2013
22. Tesniere A., et al. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ. 15, 3-12 (2008
23. Tang D., Kang R., Zeh H. J., 3rd & Lotze M. T. High-mobility group box 1 and cancer. Biochim. Biophys. Acta 1799, 131-140 (2010
24. Kostova N., Zlateva S., Ugrinova I. & Pasheva E. The expression of HMGB1 protein and its receptor RAGE in human malignant tumors. Mol. Cell. Biochem. 337, 251-258 (2010
25. Hamer M., Chida Y. & Molloy G. J. Psychological distress and cancer mortality. J. Psychosom. Res. 66, 255-258 (2009
26. Powe D. G., et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 1, 628-638 (2010
27. Wu F. & Yao P. J. Clathrin-mediated endocytosis and Alzheimers disease: an update. Ageing Res. Rev. 8, 147-149 (2009
28. Cao Y., Xiao Y., Ravid R. & Guan Z. Z. Changed clathrin regulatory proteins in the brains of Alzheimers disease patients and animal models. J. Alzheimers Dis. 22, 329-342 (2010
29. Pepe M. S. Limitations of the Odds Ratio in Gauging the Performance of a Diagnostic, Prognostic, or Screening Marker. Am. J. Epidemiol. 159, 882-890 (2004
30. Pao W., et al. Integration of molecular profiling into the lung cancer clinic. Clin. Cancer Res. 15, 5317-5322 (2009
31. Chen H. Y., et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N. Engl. J. Med. 356, 11-20 (2007
32. Seike M., et al. Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier. J. Natl. Cancer Inst. 99, 1257-1269 (2007
33. Larsen J. E., et al. Gene expression signature predicts recurrence in lung adenocarcinoma. Clin. Cancer Res. 13, 2946-2954 (2007
34. Hayes D. N., et al. Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J. Clin. Oncol. 24, 5079-5090 (2006
35. Howington J. A., Blum M. G., Chang A. C., Balekian A. A. & Murthy S. C. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143, e278S-313S (2013
36. Hung J. J., et al. Prognostic value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification on death and recurrence in completely resected stage I lung adenocarcinoma. Ann. Surg. 258, 1079-1086 (2013
37. Bolstad B. M., Irizarry R. A., Astrand M. & Speed T. P. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19, 185-193 (2003
38. Borenstein M. Introduction to meta-analysis. (John Wiley & Sons, 2009